Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) Assets Average (2021 - 2025)

Barinthus Biotherapeutics' Assets Average history spans 5 years, with the latest figure at $103.7 million for Q4 2025.

  • For Q4 2025, Assets Average fell 40.58% year-over-year to $103.7 million; the TTM value through Dec 2025 reached $103.7 million, down 40.58%, while the annual FY2025 figure was $129.2 million, 31.04% down from the prior year.
  • Assets Average reached $103.7 million in Q4 2025 per BRNS's latest filing, down from $119.4 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $285.6 million in Q2 2022 to a low of $103.7 million in Q4 2025.
  • Average Assets Average over 5 years is $211.2 million, with a median of $217.7 million recorded in 2021.
  • Peak YoY movement for Assets Average: skyrocketed 161.03% in 2022, then plummeted 40.58% in 2025.
  • A 5-year view of Assets Average shows it stood at $268.6 million in 2021, then rose by 1.56% to $272.8 million in 2022, then dropped by 18.55% to $222.2 million in 2023, then fell by 21.48% to $174.5 million in 2024, then crashed by 40.58% to $103.7 million in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Assets Average are $103.7 million (Q4 2025), $119.4 million (Q3 2025), and $135.8 million (Q2 2025).